Medico Remedies Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

Valuation Metrics Signal Renewed Price Attractiveness

As of 5 Oct 2026, Medico Remedies trades at ₹22.00, up 1.95% from the previous close of ₹21.58. The stock’s 52-week range remains wide, with a high of ₹56.99 and a low of ₹20.60, underscoring significant volatility over the past year. The company’s P/E ratio currently stands at 13.28, a marked improvement compared to many of its pharmaceutical peers, which are trading at substantially higher multiples. For instance, Ind-Swift Laboratories and Shukra Pharmaceuticals command P/E ratios of 51.93 and 80.39 respectively, reflecting very expensive valuations in contrast to Medico Remedies’ very attractive rating.

Similarly, the price-to-book value ratio for Medico Remedies is 2.43, which is moderate and suggests the stock is reasonably priced relative to its net asset value. This contrasts with several peers such as Syncom Formulations and Hester Biosciences, which trade at elevated valuations, indicating a premium that may not be justified given their fundamentals.

Enterprise value multiples further reinforce Medico Remedies’ valuation appeal. The EV to EBITDA ratio is 11.35, significantly lower than the sector heavyweights like Shukra Pharma at 56.19 and Anlon Healthcare at 37.85. This suggests that Medico Remedies is trading at a discount on an operational earnings basis, potentially offering investors a margin of safety amid sector uncertainties.

Financial Performance and Returns: A Mixed Picture

Despite the improved valuation, Medico Remedies’ recent stock returns have been disappointing relative to the benchmark Sensex. Year-to-date, the stock has declined by 56.49%, while the Sensex has fallen by 15.62%. Over the past year, the stock has lost 54.53%, compared to an 11.20% decline in the Sensex. Even over a three-year horizon, Medico Remedies has underperformed significantly, with a negative return of 68.92% versus a positive 9.24% for the Sensex.

However, the longer-term five-year return of 63.08% outpaces the Sensex’s 22.37%, indicating that the company has delivered value over a more extended period despite recent setbacks. This divergence highlights the stock’s cyclical nature and the importance of valuation in assessing investment timing.

Profitability and Efficiency Metrics

Medico Remedies’ return on capital employed (ROCE) stands at 13.58%, while return on equity (ROE) is a healthy 18.31%. These figures suggest the company is generating reasonable returns on its invested capital and equity base, supporting the case for its improved valuation. The PEG ratio of 0.39 further indicates that the stock is undervalued relative to its earnings growth potential, a stark contrast to peers such as Jagsonpal Pharmaceuticals with a PEG of 2.42, signalling overvaluation.

Comparative Valuation: Medico Remedies vs Peers

When benchmarked against its pharmaceutical and biotechnology peers, Medico Remedies’ valuation stands out as very attractive. While companies like Fredun Pharma and NGL Fine Chem are classified as expensive with P/E ratios above 30, Medico Remedies’ P/E of 13.28 is less than half that of many competitors. This valuation gap is even more pronounced when considering EV to EBITDA multiples, where Medico Remedies trades at 11.35 compared to 50.38 for Ind-Swift Laboratories and 56.19 for Shukra Pharma.

This disparity suggests that the market is pricing in significant risks or growth concerns for Medico Remedies, which may be overly punitive given the company’s solid profitability metrics and reasonable capital efficiency. The company’s micro-cap status may also contribute to its valuation discount, as smaller companies often face liquidity and visibility challenges in the market.

Market Sentiment and Rating Changes

Reflecting the evolving valuation landscape, Medico Remedies’ Mojo Grade was downgraded from Hold to Sell on 15 Sep 2026, with a current Mojo Score of 46.0. This rating change signals caution from the MarketsMOJO analytics team, likely influenced by the stock’s weak recent price performance and micro-cap risks despite its attractive valuation multiples.

Investors should weigh this downgrade against the company’s improved valuation parameters and underlying financial health. The absence of a dividend yield may also be a consideration for income-focused investors, although the company’s growth prospects and capital returns metrics remain encouraging.

Investment Considerations and Outlook

Medico Remedies’ valuation repositioning to very attractive offers a potential entry point for value-oriented investors willing to tolerate the stock’s volatility and micro-cap risks. The company’s reasonable P/E and EV multiples, combined with solid ROCE and ROE figures, suggest that the market may be undervaluing its earnings and capital efficiency.

However, the stock’s substantial underperformance relative to the Sensex over multiple time frames, including a 56.49% decline year-to-date, warrants caution. Investors should consider the broader sector dynamics, competitive pressures, and company-specific factors that may be influencing sentiment.

Given the downgrade to a Sell rating by MarketsMOJO, a prudent approach would be to monitor the stock for signs of sustained operational improvement or a catalyst that could drive re-rating. Until then, the valuation attractiveness may be offset by execution risks and market sentiment challenges.

In summary, Medico Remedies presents a compelling valuation case within the Pharmaceuticals & Biotechnology sector, especially when contrasted with its richly valued peers. Yet, the stock’s recent price weakness and rating downgrade highlight the need for careful analysis before committing capital.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →